CSI Market
Sign In | Register

Altamira Therapeutics Ltd (CYTO) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access CYTO quarterly Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Altamira Therapeutics Ltd funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2024)
12 Months 		(Dec 31 2023) (Dec 31 2022) (Dec 31 2021) (Dec 31 2020)
Operating Activities
Income-8.46
Depreciation & amortization0.13
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments-0.58
Financial Instruments and Foreign Currency Transaction0.57
Adjustments For Decrease Increase In Other Operating Receivables-
Adjustments For Increase Decrease In Prepayments0.20
Adjustments For Increase Decrease In Trade Account Payable-
Adjustments For Interest Expense1.01
Losses On Disposals Of Property Plant And Equipment-
Adjustments For Sharebased Payments0.38
Transactions Costs-
Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method0.04
Adjustment for Gain On Disposal Of Discontinued Operations-5.21
Adjustment for Deferred Income-
Income taxes0.00
Adjustments For Gains Losses On Change In Fair Value Of Derivatives0.00
Accounts Receivable0.00
Accounts Payable0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-6.11
Investing Activities
Capital Expenditures0.10
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Interest Received Classified As Investing Activities0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.12
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Increase Decrease In Cash And Cash Equivalents0.56
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities6.51
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-6.01
Total Cash Flow0.00
4 historic quarters locked

Sign in to unlock the full Altamira Therapeutics Ltd cash flow history.

Sign In Create Free Account

About Altamira Therapeutics Ltd Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001213900-25-037199

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License